Bibliography
- HARROP R, JOHN J, CARROLL MW: Recombinant viral vectors: cancer vaccines. Adv. Drug Delivery Rev. (2006) 58(8):931-947.
- HARROP R, CARROLL MW: Viral vectors for cancer immunotherapy. Front. Biosci. (2006) 11:804-817.
- HARROP R, RYAN M: Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol. Immunother. (2006) 55(9):1081-1090.
- HARROP R, CONNOLLY NB, REDCHENKO I et al.: Vaccination of colorectal cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II Trial. Clin Cancer Res. (2006) 12(11):3416-3424.
- HARROP R, DRURY N, SHINGLER W et al.: Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses (2007) (In Preparation).
- HARROP R, HAWKINS RE, ANTHONEY A et al.: An open label Phase II study of modified vaccinia ankara (MVA) expressing the tumor antigen 5T4 given in conjunction with chemotherapy: safety and immunogenicity before, during and after chemotherapy. J. Clin Oncol. Proceedings of the 2005 ASCO Annual Meeting (2005) 23(16S):2578.
- DANGOOR A, BURT D, HARROP R et al.: A vaccinia-based vaccine (TroVax) targeting the oncofetal antigen 5T4 administered before and after surgical resection of colorectal cancer liver metastases: Phase II trial. J. Clin Oncol. Proceedings of the 2006 ASCO Annual Meeting (2006) 24(18S):2574.
- KAUFMAN HL, DERAFFELE G, MITCHAM J et al.: A Phase I clinical trial of MVA expressing 5T4 and high-dose interleukin-2 (IL-2) for metastatic renal cell carcinoma. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S):12500.
- CAO A, HERNANDEZ-MCCLAIN J, WILLIS J et al.: Activity of MVA 5T4 alone or in combination with either interleukin-2, interferon-α in patients with metastatic renal cell cancer. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings Part I (2007) 25(18S):135s (Abstract no. 3069).
- AMATO R, KAREDIY M, CAO A et al.: Phase II trial to assess the activity of MVA 5T4 (TroVax) alone versus MVA 5T4 plus granulocyte macrophage colony-stimulating factor in patients with progressive hormone refractory prostate cancer. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings Part I (2007) 25(18S):241s (Abstract no. 5026).
- HOLE N, STERN PL: A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br. J. Cancer (1988) 57:237-246.
- SOUTHALL P, BOXER G, BAGSHAW K et al.: Immunological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer (1990) 61:89-95.
- STARZYNSKA T, MARSH P, SCHOFIELD P et al.: Prognostic significance of 5T4 oncofoetal antigen expression in colorectal carcinoma. Br. J. Cancer (1994) 69:899-902.
- GRIFFITHS RW, GILHAM DE, DANGOOR A et al.: Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br. J. Cancer (2005) 93(6):670-677.
- BARROW KM, WARD CM, RUTTER J, ALI S, STERN PL: Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Devel. Dynamics (2005) 233(4):1535-1545.
- CARSBERG C, MYERS KA, STERN PL: Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in ephithelial cells. Int. J. Cancer (1996) 68(1):84-92.
- CARROLL MW, RESTIFO NP: Poxviruses as vectors for cancer immunotherapy. In: Cancer Vaccines and Immunotherapy. Stern PL, Peter CL, Beverly MC. (Eds), Cambridge University Press, Cambridge, UK (2000):47-65.
- SUTTER G, MOSS B: Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA (1992) 89:10847-10851.
- ROCHLITZ C, FIGLIN R, SQUIBAN P et al.: Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med. (2003) 5(8):690-699.
- EDER J, KANTOFF P, ROPER K et al.: A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. (2000) 6(5):1632-1638.
- MARSHALL J, HOYER R, TOOMEY M et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. (2000) 18(23):3964-3973.
- MARLOW S: Trovax Gene Therapy Vaccine Product: Investigator's Brochure, Oxford Biomedica, Oxford, UK (2006).
- REDCHENKO I, HARROP R, RYAN MG, HAWKINS RE, CARROLL MW: Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology (2006) 118:50-57.
- MOTZER R, MAZUMDAR M, BACIK J et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. (1999) 17:2530-2540.
- YANG J, SHERRY R, STEINBERG S et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21:3127-3132.
- TANNOCK I, DE WIT R, BERRY W et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. (2004) 351(15):1502-1512.
- PETRYLAK D, TANGEN C, HUSSAIN M et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. (2004) 351(15):1513-1520.
- RINI B, BOK R, SMALL E: Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J. Clin. Oncol. (2003) 21(1):99-105.
- SMALL E, REESE D, UM B et al.: Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. (1999) 5:1738-1744.
- ESCUDIER B, EISEN T, STADLER WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):125-134.
- MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):115-124.
- HUANG S, HOUGHTON P: Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. (2003) 3(4):371-377.
- DUTCHER J, HUDES G, MOTZER R: Preliminary report of a Phase I study of intravenous (IV) CCI-779 given in combination with interferon-(IFN) to patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin Oncol. (2003) 22:213 (Abstract 854).
- HUDES G, CARDUCCI M, TOMCZAK P et al.: Temsirolimus, interferon-α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. (2007) 356(22):2271-2281.
- SCHLOM J, ARLEN P, GULLEY J: Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res. (2007) 13(13):3776-3781.